Clinical Efficacy of TNF-Kinoid in Patients With Rheumatoid Arthritis

Inclusion Criteria: * Has had a diagnosis of RA according to the revised ACR criteria (Aletaha et al. 2010) for at least 6 months. * Has been treated with and tolerated MTX for at least 3 months prior to the first administration of study product, - Has at least four swollen joints/66 and/or four tender joints/68, * Has CRP ≥ 10 mg/L at screening. * Is positive for rheumatoid factor (RF) or anti-cyclic citrullinated peptides (CCP) antibodies at screening. Exclusion Criteria: * Has inflammatory rheumatic disease other than RA * Has been treated with non-biological DMARDs/systemic immunosuppressives * Has been treated with leflunomide within 12 weeks prior to first administration of study product. * Has received intra-articular, intramuscular (IM), or intravenous (IV) corticosteroids * Has received infliximab, etanercept, adalimumab, certolizumab, golimumab; another TNFα antagonist; or rituximab prior to the study. * Has been treated with any other biological DMARDs